Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, MOTS-c improves insulin sensitivity, enhances glycolysis, reduces oxidative stress, and shows protective effects in models of metabolic syndrome, aging, and ischemia-reperfusion injury8135146.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, MOTS-c is a 16-amino-acid mitochondrial-derived peptide that translocates to the nucleus under metabolic stress and regulates glucose and lipid metabolism largely via activation of AMPK and modulation of mTOR and folate-cycle–linked pathways854140146.
Liraglutide
GCG
MOTS-c
MT-RNR1
Both peptides fall into a similar broad context as Metabolic peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while Liraglutide is more of a hormone peptide and MOTS-c is better described as a mitochondrial peptide. They also influence different molecular systems, with Liraglutide tracking more closely to GLP-1 receptor while MOTS-c centers more on Mitochondrial membrane. Liraglutide has a more synthetic analog origin, while MOTS-c is closer to mitochondrial-encoded background and their development context also differs, with Liraglutide approved while MOTS-c is in Preclinical development. Liraglutide takes the form of a peptide conjugate, whereas MOTS-c is closer to a linear peptide, Liraglutide incorporates palmitoylation features that are not part of MOTS-c; while their sequence patterns also diverge, with Liraglutide showing alpha-helical domain features and MOTS-c showing hydrophobic domain features.